Introduction: Examination of clinical and preclinical pharmacologic data relating to abuse liability of l‐deprenyl (selegiline) *

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Clinical pharmacology and therapy

• Publication date

  1994-12-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1038/clpt.1994.201PMID 7995013
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenil

  2005cited by this paper
• Pharmacokinetic aspects of l‐deprenyl (selegiline) and its metabolites *

  1994cited by this paper
• Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease.

  1993cited by this paper
• The discriminative stimulus effects of cocaine in pigeons.

  1993cited by this paper
• Evaluation of the stereoisomers of deprenyl for amphetamine-like discriminative stimulus effects in rats.

  1993cited by this paper
• Preclinical Evaluation of l-Deprenyl: Lack of Amphetamine-Like Abuse Potential

  1993cited by this paper
• The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic

  1992cited by this paper
• A review of the pharmacology of selegiline

  1991cited by this paper
• Effect of deprenyl on the progression of disability in early Parkinson's disease.

  1989cited by this paper
• Increased life expectancy resulting from addition of l-deprenyl to Madopar® treatment in Parkinson's disease: A longterm study

  1985cited by this paper
• Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors

  1984cited by this paper
• Further investigation of the discriminative stimulus properties of MDA.

  1984cited by this paper
• Discrimination of the amphetamine cue. Effects of A, B and mixed type inhibitors of monoamine oxidase.

  1984cited by this paper
• Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys.

  1984cited by this paper
• Deprenyl (selegiline): the history of its development and pharmacological action

  1983cited by this paper
• Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.

  1983cited by this paper
• (-)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease.

  1983cited by this paper
• Evidence that a preferred substrate for type B monoamine oxidase mediates stimulus properties of MAO inhibitors: a possible role for beta-phenylethylamine in the cocaine cue.

  1980cited by this paper
• Deprenyl is metabolized to methamphetamine and amphetamine in man.

  1978cited by this paper
• Stimulus properties of d-amphetamine as compared to l-amphetamine.

  1978cited by this paper
• Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study.

  1977cited by this paper
• Biological Sciences: Human Brain Monoamine Oxidase: Multiple Forms and Selective Inhibitors

  1972cited by this paper
• Multiple Forms of Human Brain Mitochondrial Monoamine Oxidase

  1970cited by this paper
• Some observations upon a new inhibitor of monoamine oxidase in brain tissue.

  1968cited by this paper
• Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer.

  1965cited by this paper

• Monoamine oxidase A rather than monoamine oxidase B inhibition increases nicotine reinforcement in rats

  2006influential citation
• The Abuse Liability and Therapeutic Potential of Drugs Evaluated for Cocaine Addiction as Predicted by Animal Models

  2003cites this paper
• Orphan neurones and amine excess: the functional neuropathology of Parkinsonism and neuropsychiatric disease.

  1998cites this paper
• Psychoactive smoke

  1996cites this paper
• Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research.

  1996cites this paper
• Deprenyl — Past and Future

  1996cites this paper